8
Participants
Start Date
May 31, 2013
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
DKN-01 300 mg
300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
DKN-01 600 mg
600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
Standard of Care
Current approved standard of care
Emory University Hospital, Atlanta
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Leap Therapeutics, Inc.
INDUSTRY